KURA

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Retrieved on: 
Monday, February 26, 2024
AML, Azacitidine, Menin, KMT2A, Safety, Prognosis, FLT3, Pharmacokinetics, Venetoclax, Patient, KURA, Kura, Acute myeloid leukemia, LDAC, Cancer, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

Key Points: 
  • “Roughly half of patients with relapsed or refractory NPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is particularly poor,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Trial participants will be enrolled in one of five dose escalation cohorts, including a cohort of NPM1-mutant AML patients with a documented FLT3 co-mutation, who will be treated in combination with the FLT3 inhibitor gilteritinib.
  • Kura is conducting a series of studies to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations.
  • Preclinical data for menin inhibitors in combination with multiple FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone.

Kura Oncology to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Thursday, February 22, 2024
KURA, SAN, Conference, Cancer

ET / 6:10 a.m. PT and participation in the Leukemia Corporate Panel at 12:50 p.m.

Key Points: 
  • ET / 6:10 a.m. PT and participation in the Leukemia Corporate Panel at 12:50 p.m.
  • ET / 9:50 a.m. PT on March 4, 2024;
    A fireside chat at the Leerink Partners Global Biopharma Conference in Miami at 11:20 a.m.
  • ET / 8:20 a.m. PT on March 12, 2024; and
    A fireside chat at the Barclays Global Healthcare Conference in Miami at 9:00 a.m.
  • Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com , with archived replays available following all three events.

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
KURA, SAN, Webcast, Cancer

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024.

Key Points: 
  • SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024.
  • Kura’s management will host a webcast and conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, February 2, 2024
SAN, Employment, KURA, Cancer, Compensated emancipation

SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 59,750 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan.

Key Points: 
  • SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 59,750 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan.
  • The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has an exercise price per share equal to $21.02 per share, the Company’s closing sales price on February 1, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates.
  • The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan and the terms and conditions of an applicable stock option agreement covering the grant.

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, January 30, 2024
KURA, Failure, Acute myeloid leukemia, Venetoclax, Research, Division, MHS, Patient, Safety, QT interval, AML, Bone marrow, MBBS, QD, Yale Cancer Center, Disease, Therapy, Postcholecystectomy syndrome, Risk, ID, Cancer, Kura, Pharmaceutical industry

Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.

Key Points: 
  • Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.
  • The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was 53% (8/15).
  • As of the data cutoff, 80% (16/20) of patients remain on trial, including 100% (11/11) of all NPM1-m patients.
  • “We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Kura Oncology Announces Oversubscribed $150 Million Private Placement

Retrieved on: 
Wednesday, January 24, 2024
Research, SVB Securities, Prospectus, Cancer, Sale, Investment, Kura, Exercise, KURA, Security (finance)

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 shares of its common stock at a price of $17.25 per share, representing a premium of approximately 29% to Kura’s closing price on January 23, 2024, and pre-funded warrants to purchase 7,318,886 shares of its common stock at price per pre-funded warrant of $17.2499 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. The pre-funded warrant exercise price is $0.0001 per share. Kura anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. The private placement is expected to close on or about January 26, 2024, subject to customary closing conditions.

Key Points: 
  • Kura anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about January 26, 2024, subject to customary closing conditions.
  • Leerink Partners acted as the sole placement agent for the private placement.
  • Kura has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the pricing of the private placement.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on: 
Friday, December 8, 2023
Princess, Leukemia & Lymphoma Society, Partnership, Research, Bone marrow, KURA, Drug, Kura, SAN, Pedal, Clinical trial, Cancer, LLS, Leukemia, Patient, Acute leukemia, Pharmaceutical industry

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points: 
  • “We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
  • “Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
  • PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
  • Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

Retrieved on: 
Tuesday, November 28, 2023
Cancer, KURA, Hematology, SAN

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m.

Key Points: 
  • SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m.
  • ET / 11:00 a.m. PT on Tuesday, December 5, 2023.
  • A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com , with a replay available shortly after the live event.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Retrieved on: 
Thursday, November 2, 2023
Mirati, NSCLC, Cancer, Patient, Mirati Therapeutics, Trial of the century, KURA, SAN, FTI, Pharmaceutical industry

“Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.

Key Points: 
  • “Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Preclinical work demonstrates the ability of adagrasib, in combination with a FTI, to improve patient outcomes,” said Alan Sandler, M.D., Chief Medical Officer, Mirati Therapeutics.
  • “This collaboration exemplifies the potential combinability of adagrasib as a key differentiation from other KRASG12C inhibitors.”
    Under the terms of the agreement, Kura will sponsor the Phase 1 study of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC.
  • Mirati will supply Kura with adagrasib for the study.